A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March 2013 issue of Nature by Prof Dimmler, Boon, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based therapy for Myocardial Infarction: Ankaflavin improves ageing- and stress-associated decline in cardiac function via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10). By treating aged people who are susceptible to cardiac diseases with Ankaflavin activators, one may prevent ageing-associated decline in cardiac function. Together, this study suggests that pharmacological formulations encompassing ” Ankaflavin activators” may be used to improve cardiac function after myocardial infarction.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Amount: $500*
Undisclosed information: How Ankaflavin increases the expression of PNUTS/PPP1R10
To cite: Boominathan, Regenerative Stem cell therapy for Myocardial Infarction: Ankaflavin improves ageing- and stress-associated decline in cardiac function via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 3/February/2015, 12.41 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
